Cisplatin in Tanzania: NEMLIT level, who can prescribe it and STG references

Cisplatin is on Tanzania's National Essential Medicines List (NEMLIT, 7th edition, 2026) at level S (zonal, special and national hospitals). It is not on the DukaDawa pharmacy network yet, so we show no brands or prices for it. The Standard Treatment Guidelines mention it in 8 or more sections.

Last updated

New to DukadawaRx? Register as a prescriber. Licensed prescribers only; we verify your registration before you can prescribe.

Is cisplatin available on the DukaDawa pharmacy network?

Not yet. Cisplatin is not in the DukaDawa network catalogue, so we have no brands, prices or stock for it.

Prescribers can still write it on a DukadawaRx prescription, and we show it here as soon as a network pharmacy lists it.

Is cisplatin on the NEMLIT, and who can prescribe it?

Yes. Cisplatin is on Tanzania's National Essential Medicines List (NEMLIT, 7th edition, 2026) at level S (zonal, special and national hospitals). At level S it may be prescribed by specialists.

Level
S (zonal, special and national hospitals)
Category
Antineoplastics, Immunosuppressives and Immunomodulators
Listed forms
Powder for injection: 50 mg; 10mg in vial.
Page
NEMLIT, p. 13
Who may prescribe at each NEMLIT level (STG/NEMLIT 7th edition, Part I, Table 1). Levels listed for this medicine are highlighted.
LevelFacilityWho may prescribe
ADispensarySpecialist, Medical Officer, Dental Officer, Assistant Medical Officer, Clinical Officer, Assistant Clinical Officer
BHealth centreSpecialist, Medical Officer, Dental Officer, Assistant Medical Officer, Clinical Officer
CCouncil or district hospitalSpecialist, Medical Officer, Dental Officer, Assistant Medical Officer
DRegional referral hospitalSpecialist, Medical Officer, Dental Officer
S (listed)Zonal, special and national hospitalsSpecialist

A medicine is listed from the lowest facility level where it should be available.

Where is cisplatin in the Standard Treatment Guidelines?

The Standard Treatment Guidelines (7th edition, 2026) mention cisplatin in 8 or more sections, most often section 22.7.1 Lung Cancer > Non-small cell lung Cancer (p. 606). See the STG for treatment details.

  • 22.7.1 Lung Cancer > Non-small cell lung Cancer, p. 606
  • 22.2.1 Gynecological Malignancies > Cancer of the Uterine Cervix, p. 569
  • 22.5.8 Head and Neck Cancers > Thyroid Carcinoma, p. 592
  • 22.8.4 Genitourinary Malignancies > Testicular Cancer, p. 611
  • 22.2.5.2 Gynecological Malignancies > Gestational Trophoblastic Disease > Malignant type (Gestational Trophoblastic neoplasia—GTN), p. 575
  • 22.5.3 Head and Neck Cancers > Hypopharyngeal Cancers, p. 587
  • 22.6.3 Gastrointestinal Malignancies > Gastric Cancer, p. 598
  • 22.7.2 Lung Cancer > Small cell lung cancer, p. 607

Sections that mention Cisplatin, most mentions first. Positions only: see the STG for treatment details.

All antineoplastics, immunosuppressives and immunomodulators on the NEMLIT

Sources

  • Standard Treatment Guidelines and National Essential Medicines List (STG/NEMLIT), 7th edition, 2026, Ministry of Health, United Republic of Tanzania

Page last updated

STG positions are section numbers and printed page numbers only.

This page supports licensed prescribers and pharmacists. It is not medical advice and does not replace the Standard Treatment Guidelines, the product information or professional judgement. Prices and stock change often: confirm with the pharmacy.

For licensed prescribers and pharmacists. Not medical advice. Check the Standard Treatment Guidelines before prescribing.